Condition
Broader IBD news covering Crohn's disease, ulcerative colitis, research, treatments, monitoring, and patient care.
Page 55 of 88 · 4195 articles
Upadacitinib is already used for some patients with UC and Crohn's; this article offers a structured way to think about why it can act quickly in refractory cases and what evidence would be needed to move from short‑term...
Epigenetic control of intestinal epithelial cells can shape gut microbes and influence colitis severity; understanding SETD2’s role could point to new mechanistic targets for IBD research and microbiome-directed...
Researchers found that immune cells detect the gut-associated yeast Debaryomyces hansenii via Dectin-1 and Card9, and the yeast was enriched in Crohn’s disease ulcers. That suggests a possible microbial–immune link...
If epithelial cells themselves retain disease-linked programs, that could help explain persistent intestinal abnormalities in Crohn’s disease even during remission and point to new biomarker or therapeutic targets...
Based on the title and source metadata, this appears to be a basic science related to Crohn's disease, Inflammatory bowel disease, and Genetics and genomics. The original article is from msn.com.
Fatigue is a frequent, impactful symptom in Crohn’s disease that often goes unmeasured in clinic visits. Knowing which assessment tools exist can help patients and clinicians recognize and address fatigue.
The work helps bridge genetic association signals and the specific immune cells in the intestine where they may act, offering new candidate genes and a method that can probe rare cell types important to IBD biology.
ILC3s live in the intestine and help regulate barrier function and inflammation, so mapping how genetic variants affect gene regulation in these rare cells helps connect inherited risk signals to plausible biology for...
This profile shows how someone with Crohn’s disease can continue competitive athletic pursuits while managing the condition. It highlights common issues for people with IBD—remission, stress-related flares,...
Mapping 3D genome contacts in rare gut immune cells connects Crohn’s disease genetic risk variants to specific genes and pathways, which can clarify disease mechanisms and guide future drug-target research. The study...
ILC3s are rare but important for gut immunity; linking Crohn’s disease genetic risk to the genes they regulate helps move from statistical association toward biological mechanisms that could explain disease pathways.
This study helps move beyond assigning GWAS risk variants to the nearest gene by mapping 3D promoter contacts in gut-enriched ILC3s, so it uncovers new candidate genes and pathways that could explain Crohn’s and other...
The study helps explain how noncoding genetic variants may influence Crohn’s disease by altering 3D genome interactions in rare gut-associated immune cells (ILC3s), pointing to new genes and pathways that could be...
Researchers are exploring new antioxidant nanozymes that can be given orally to reduce intestinal inflammation in lab models. If these approaches eventually translate to humans, they could become an additional strategy...
UGI involvement in children with IBD was common and linked to a more severe disease course — lower remission rates and more frequent need for biologic therapy — which could affect monitoring and treatment planning.
This research links a specific gut-associated yeast to activation of innate immune pathways (Dectin-1–Card9) that drive inflammatory signaling. For people with Crohn disease, it suggests fungal members of the gut...
Cure8 found this source from Inflammatory bowel diseases, but the page could not be read reliably yet. It is tagged for Inflammatory bowel disease and Pregnancy and fertility. Open the original article for the full...
Dietary patterns are being studied as therapies for pediatric IBD because they may help induce remission or improve disease control without drugs.
Diet-based therapies like CDED + PEN may help control Crohn’s symptoms and improve nutrition without adding medications. This study suggests some adults can maintain remission and gain nutritional benefits over a year...
This review examines a noninvasive neuromodulation strategy (ta‑VNS) that might modulate immune and gut‑barrier biomarkers in IBD and could become an adjunctive therapy if validated in trials. Patients and clinicians may...
Based on the title and source metadata, this appears to be a basic science related to Ulcerative colitis, Inflammatory bowel disease, and Biomarkers. The original article is from Biochemistry and Biophysics Reports.
People with moderate-to-severe Crohn’s disease may be interested because the study explores a new, repurposed drug (vorinostat) that targets epigenetic and immune pathways and includes a plan to move responding...
The study tests mirikizumab in routine clinical practice against standard biologic therapies to see if it lowers healthcare needs and improves symptoms and quality of life for people with Crohn’s disease or ulcerative...
EEN is being evaluated as a non‑pharmacologic induction therapy in adults with active and complicated Crohn’s disease; results could inform whether EEN helps induce remission, improve nutrition, and impact inflammation...
FAP appears linked to both inflammation and fibrosis in IBD; distinguishing cellular versus extracellular FAP might help develop or validate fibrosis biomarkers that detect fibrostenotic disease.
People with Crohn’s disease may benefit from research that identifies the specific genes and immune pathways driving inflammation — this study points to over 100 genes in gut ILC3 cells that could explain how genetic...
Shorter height at IBD diagnosis was more common in Hispanic/Latino children and those without private insurance, which may reflect inequities in timely diagnosis and access to nutrition and care—issues that can affect...
The study identifies a specific gut microbe and a bile-acid metabolite that reduced inflammation in a mouse colitis model and implicates STAT3/NF-κB pathways — a potential new avenue for microbiome-based therapeutics for...
This review summarizes evidence on robotic surgery for IBD, which could affect surgical choices and expectations about recovery and risks for patients needing colorectal or pelvic operations. It suggests robotic...
FDA drug-label updates change how a medicine should be used and monitored. For people with ulcerative colitis and other immune-mediated diseases, this label highlights safety risks and limits on combining tofacitinib...
This is an updated FDA drug label for tofacitinib, a JAK inhibitor that is approved for ulcerative colitis and other immune conditions.
The appendix in conventional UC appears to be inflamed early and then remodels to fibrous obliteration over decades, which could influence thinking about timing or rationale for appendectomy-based interventions.
Krill oil improved colitis signs and intestinal barrier markers in a mouse model and changed colon gene expression linked to cell adhesion—findings that may interest people tracking dietary or supplemental approaches for...
Older adults with UC face different risks and treatment trade-offs than younger patients — higher infection and cancer risks, medication toxicities, and challenges with diagnosis and colonoscopy. Understanding these...
The study links a common environmental pollutant (UV-328) to worsened experimental colitis and altered cholesterol metabolism, suggesting environmental exposures might influence IBD activity and could point to new...
MSCs are an active research area for IBD because they may reduce harmful immune activity and help heal intestinal tissue. Patients following emerging biologic and cell therapies may want to know how MSCs could fit into...
Surgery for IBD has become less common since modern biologic therapies, but a noticeable number of patients—especially with Crohn’s disease and poor nutrition—still progress to operations. Understanding who remains at...
Cure8 found this source from Digestive diseases and sciences, but the page could not be read reliably yet. It is tagged for Inflammatory bowel disease and Community and awareness. Open the original article for the full...
Identifying simple features at diagnosis that predict a disabling 5‑year course could help patients and clinicians plan monitoring and treatment intensity earlier after Crohn’s diagnosis.
If approved, a vedolizumab biosimilar could increase treatment options and potentially lower costs or improve access to an established biologic used for moderate-to-severe Crohn’s disease and ulcerative colitis....
Regulatory review starts a formal approval process that could lead to a lower-cost biosimilar alternative to Entyvio (vedolizumab), potentially improving access to a biologic used in Crohn’s disease and ulcerative...
The review suggests that allergic-type (type 2) immune pathways may play a meaningful role in some people with Crohn's disease, which could point to new treatment options that target IgE, Th2 cytokines, epithelial...
New leadership hires and a planned Phase 2 program mean prifemilast — an oral PDE4B-selective investigational drug — is moving toward larger IBD studies. People with IBD who want more oral treatment options or who follow...
High out-of-pocket costs and insurance practices can force people with Crohn’s and other chronic autoimmune diseases to delay or stop biologic therapy, which has direct consequences for disease control and quality of...
A vedolizumab biosimilar could increase access to an important biologic treatment for people with moderate‑to‑severe UC and Crohn’s disease by offering a potentially lower‑cost alternative. Regulatory review by the FDA...
This review suggests SSRIs and SNRIs may influence both brain and gut pathways relevant to symptom burden in IBD and DGBI — potentially improving mood, pain, motility, and aspects of inflammation. That could matter for...
The study identifies Gardenia-derived pectic polysaccharides that reduced inflammation and restored colon health in a mouse colitis model, suggesting a possible microbiome-mediated protective effect relevant to IBD...
